← Back to Search

Behavioral Intervention

Addiction Risk Feedback Program for Substance Abuse (ARFP Trial)

N/A
Recruiting
Led By Danielle Dick, PhD
Research Sponsored by Rutgers, The State University of New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Summary

This trial aims to see if a personalized feedback program can help reduce risky substance use in young adults aged 18-25 years.

Who is the study for?
This trial is for young adults aged 18-25 living in the U.S. who speak English and are willing to give informed consent. It's not open to those outside this age range, non-U.S. residents, or anyone unwilling to agree formally to participate.
What is being tested?
The study is examining a new personalized feedback program designed to help reduce risky substance use among emerging adults. Participants will complete this intervention program aimed at lowering their chances of developing substance use disorders.
What are the potential side effects?
Since the intervention involves an addiction risk feedback program rather than medication, traditional physical side effects are not expected; however, participants may experience emotional or psychological responses during the process.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Alcohol Consumption
Alcohol Problems
Drug Use Problems
+2 more
Secondary study objectives
Addiction Risk Program Satisfaction
Anxiety and Depressive Symptoms
Feelings About Results
+4 more

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: Waitlist Control - Psychoeducation OnlyExperimental Treatment1 Intervention
Participants in this condition will not receive their personalized risk estimates until the end of the study. They will receive psychoeducation about ways to reduce substance use and associated harm at the time that the active conditions receive their estimates and associated follow-up content.
Group II: Risk estimates + Genetic CounselorActive Control1 Intervention
Participants in this condition will complete the prevention program in which individuals receive their personalized risk estimates, followed by a follow-up appointment with a genetic counselor.
Group III: Risk estimates + PsychoeducationActive Control1 Intervention
Participants in this condition will complete the prevention program in which individuals receive their personalized risk estimates, followed by psychoeducation about ways to reduce substance use and associated harm.
Group IV: Risk estimates + Online CBT ModulesActive Control1 Intervention
Participants in this condition will complete the prevention program in which individuals receive their personalized risk estimates, followed by on-line cognitive behavioral therapy (CBT)-based modules to assist with controlling substance use.

Find a Location

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH
2,543 Previous Clinical Trials
3,248,926 Total Patients Enrolled
153 Trials studying Substance Abuse
707,200 Patients Enrolled for Substance Abuse
Rutgers, The State University of New JerseyLead Sponsor
440 Previous Clinical Trials
64,932 Total Patients Enrolled
Danielle Dick, PhDPrincipal InvestigatorRutgers Robert Wood Johnson Medical School
1 Previous Clinical Trials
338 Total Patients Enrolled
~112 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top